MIAMI--(BUSINESS WIRE)--June 29, 2006--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN - News) today confirmed that Shire plc has launched Daytrana(TM) (methylphenidate transdermal system), the first and only transdermal medication approved to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in children aged six to twelve years, and that the product is now available in retail pharmacies. Shire, the market leader in ADHD, is the exclusive, global licensee of Daytrana(TM), which was developed and is manufactured by Noven.
